Bivalirudin
Immune modulation
Immune balance, inflammation, or resilience support
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Immune / inflammatory modulator
- Primary mechanism
- Immune or inflammatory pathway modulation
- Primary market use
- Immune modulation
Pharmacology
- Molecular weight (Da)
- 2180.29
- Oral bioavailability
- Route-dependent / verify
- Half-life
- ~2–12 h small-molecule class estimate
- Route tags
- Route-dependent / verify
- Evidence level
- MCE product listing / research chemical signal
- Clinical status
- Research chemical/reference listing
- Value-for-money score
- 6 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Bivalirudin TFA, a hirudin analog and anticoagulant, is a direct thrombin inhibitor. Bivalirudin TFA inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin . In addition, Bivalirudin TFA also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin TFA can be used for the research of thrombotic diseases and others .